Account

Sign in to access your account and subscription

Federal Circuit Finds Claims Directed to DNA Primers and Methods of Use Unpatentable

The Federal Circuit's decision in <i>Univ. of Utah Research Found. v. Ambry Genetics Corp.</i> is the latest in the series of <i>Myriad</i> cases dealing with the patentability of genetic material.

16 minute read January 31, 2015 at 11:00 PM
By
Veronica Mullally Munoz
Federal Circuit Finds Claims Directed to DNA Primers and Methods of Use Unpatentable

The Federal Circuit's decision in Univ. of Utah Research Found. v. Ambry Genetics Corp., 2014-1361, -1366 (Fed. Cir. Dec. 17, 2014) is the latest in the series of Myriad cases dealing with the patentability of genetic material.

This premium content is locked for The Intellectual Property Strategist subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.

October 01, 2026